Product Code: 25369
KEY FINDINGS
The global glucose monitoring system CGMS market is anticipated to grow at a CAGR of 22.31%, and the SMBG market is estimated to grow at 5.22% over the forecast period of 2019-2028. The various factors stimulating global market growth are surge in diabetes incidences, rise in healthcare expenditure, growing emphasis on R&D, technology amalgamation, economical CGMS AND SMBG, technological development in GMS devices, and growing awareness among people.
MARKET INSIGHTS
The advent of continuous glucose monitoring systems (CGMS) is a major achievement in glucose monitoring for diabetic patients. Conventionally, CGMS faced competition from finger-based self-monitoring blood glucose (SMBG) devices, as they are affordable, easy-to-use, and easily approved by the authorities. However, CGMS has been well accepted in the US, and increasing its presence in other countries as well. There is an exceptional rise in the diabetic population all over the world, which is driving the market. Eating habits, changing lifestyles, and less physical activities are the major causes of type 2 diabetes in adults. However, type 1 diabetes has also increased.
Government regulations are hindering the growth of the market. The glucose monitoring market is highly regulated by strict rules and approval issues from government authorities, especially the US FDA, which has very stringent regulations. All the companies are focusing on developing innovative and technologically advanced products to stay competitive in the market. The sensors category in the CGMS market by component type segment captured the largest market share in 2019. The sensors dispense signals to show the real-time glucose level of the patients. Lancets are the fastest-growing component type in the SMBG market.
REGIONAL INSIGHTS
The geographical analysis of the global glucose monitoring system market includes market evaluation of North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is the fastest-growing region for both, SMBG and CGMS market. This is mainly due to the growing prevalence of diabetes in the region.
COMPETITIVE INSIGHTS
The introduction of new technologies, coupled with mergers and acquisitions, is resulting in a high competitive rivalry in the market. Some of the eminent players operating in the market are Ypsomed, Abbott Diagnostic, Medtronic, Inc, Terumo, Wockhardt, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARIES
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
- 3.1. MARKET DEFINITION
- 3.2. KEY DRIVERS
- 3.2.1. RISE IN THE INCIDENCE OF DIABETES
- 3.2.2. INCREASE IN HEALTHCARE EXPENDITURE
- 3.2.3. INCREASING FOCUS ON RESEARCH AND DEVELOPMENT
- 3.2.4. TECHNOLOGY INTEGRATION
- 3.2.5. INCREASING CGMS AND SMBG AFFORDABILITY
- 3.2.6. TECHNOLOGICAL ADVANCES IN GMS DEVICES
- 3.2.7. AWARENESS AMONG THE GENERAL POPULATION
- 3.3. KEY RESTRAINTS
- 3.3.1. HINDRANCE FROM GOVERNMENT REGULATIONS
- 3.3.2. INADEQUATE REIMBURSEMENT OPTIONS FOR CONTINUOUS GLUCOSE MONITORING DEVICES
- 3.3.3. LACK OF AWARENESS OF THE DIAGNOSTIC OPPORTUNITIES
- 3.3.4. INTENSE COMPETITION AMONG VENDORS
- 3.3.5. INACCURACY IN READING OF GMS DEVICES
4. KEY ANALYTICS
- 4.1. PORTER'S FIVE FORCE ANALYSIS
- 4.1.1. THREAT OF NEW ENTRY
- 4.1.2. THREAT OF SUBSTITUTION
- 4.1.3. BUYER'S POWER
- 4.1.4. SUPPLIER'S POWER
- 4.1.5. COMPETITIVE RIVALRY
- 4.2. KEY BUYING CRITERIA
- 4.3. REGULATION OF BLOOD SUGAR
- 4.4. VALUE CHAIN ANALYSIS
- 4.5. OPPORTUNITY MATRIX
- 4.6. VENDOR LANDSCAPE
- 4.7. KEY INVESTMENT INSIGHTS
5. CGMS MARKET BY COMPONENT TYPE
- 5.1. SENSORS
- 5.2. TRANSMITTER AND RECEIVERS
- 5.3. INTEGRATED INSULIN PUMPS
6. CGMS MARKET BY END-USER
- 6.1. HOME SETTINGS
- 6.2. DIAGNOSTICS AND CLINICAL
- 6.3. HOSPITAL
7. CGMS MARKET BY DEMOGRAPHICS
- 7.1. ADULT POPULATION (>14YEARS)
- 7.2. CHILD POPULATION (≤14YEARS)
8. SMBG MARKET OVERVIEW
9. SMBG MARKET BY COMPONENT TYPE
- 9.1. TEST STRIPS
- 9.2. GLUCOSE METER
- 9.3. LANCETS
10. SMBG MARKET BY END USER
- 10.1. HOME SETTINGS
- 10.2. CLINICAL
- 10.3. HOSPITAL
11. SMBG MARKET BY APPLICATION
- 11.1. TYPE 1 DIABETES
- 11.2. TYPE 2 DIABETES
- 11.3. GESTATIONAL DIABETES
12. GEOGRAPHICAL ANALYSIS
- 12.1. NORTH AMERICA
- 12.1.1. THE UNITED STATES
- 12.1.1.1. THE UNITED STATES HEALTH AND HEALTHCARE
- 12.1.1.2. THE UNITED STATES PHARMACEUTICAL MARKET
- 12.1.2. CANADA
- 12.1.2.1. CANADA HEALTH AND HEALTHCARE
- 12.1.2.2. CANADA PHARMACEUTICAL MARKET
- 12.1.2.3. CANADA DIABETES MARKET
- 12.2. EUROPE
- 12.2.1. GERMANY
- 12.2.1.1. GERMANY HEALTH AND HEALTHCARE
- 12.2.1.2. GERMANY PHARMACEUTICAL MARKET
- 12.2.2. THE UNITED KINGDOM
- 12.2.2.1. THE UNITED KINGDOM HEALTH AND HEALTHCARE
- 12.2.2.2. THE UNITED KINGDOM HEALTHCARE PROVISION
- 12.2.2.3. THE UNITED KINGDOM PRIVATE SECTOR INVOLVEMENT
- 12.2.2.4. THE UNITED KINGDOM PHARMACEUTICALS
- 12.2.3. FRANCE
- 12.2.3.1. FRANCE HEALTH AND HEALTHCARE
- 12.2.3.2. FRANCE HEALTHCARE PROVISION
- 12.2.4. RUSSIA
- 12.2.4.1. RUSSIA HEALTH AND HEALTHCARE
- 12.2.4.2. RUSSIA PHARMACEUTICAL SERVICES
- 12.2.5. ITALY
- 12.2.5.1. ITALY HEALTH AND HEALTHCARE
- 12.2.5.2. ITALY HEALTHCARE PROVISION
- 12.2.5.3. ITALY PHARMACEUTICAL MARKET
- 12.2.6. BELGIUM
- 12.2.7. POLAND
- 12.2.8. REST OF EUROPE (ROE)
- 12.3. ASIA PACIFIC
- 12.3.1. CHINA
- 12.3.1.1. CHINA HEALTH AND HEALTHCARE
- 12.3.1.2. CHINA PHARMACEUTICAL MARKET
- 12.3.1.3. CHINA DIABETES MARKET
- 12.3.1.4. MARKET TRENDS
- 12.3.2. INDIA
- 12.3.2.1. INDIA HEALTH AND HEALTHCARE
- 12.3.2.2. INDIA REGULATORY CHANGES
- 12.3.2.3. INDIA PHARMACEUTICAL MARKET
- 12.3.2.4. INDIA DIABETES MARKET
- 12.3.3. AUSTRALIA
- 12.3.4. JAPAN
- 12.3.4.1. JAPAN HEALTH AND HEALTHCARE
- 12.3.4.2. JAPAN PHARMACEUTICAL MARKET
- 12.3.4.3. JAPAN DIABETES MARKET
- 12.3.4.4. MARKET TRENDS
- 12.3.5. SOUTH KOREA
- 12.3.6. INDONESIA
- 12.3.7. MALAYSIA
- 12.3.8. PHILIPPINES
- 12.3.9. THAILAND
- 12.3.10. VIETNAM
- 12.3.11. REST OF APAC
- 12.4. REST OF WORLD
- 12.4.1. LATIN AMERICA
- 12.4.1.1. BRAZIL HEALTH AND HEALTHCARE
- 12.4.1.2. BRAZIL PHARMACEUTICAL MARKET
- 12.4.1.3. MEXICO HEALTH AND HEALTHCARE
- 12.4.1.4. MEXICO PHARMACEUTICAL MARKET
- 12.4.2. MIDDLE EAST AND AFRICA
13. COMPANY PROFILES
- 13.1. ABBOTT
- 13.2. APEX BIOTECHNOLOGY CORPORATION
- 13.3. ARKRAY INC
- 13.4. ASCENSIA
- 13.5. B BRAUN MELSUNGEN AG
- 13.6. BECTON DICKINSON AND COMPANY
- 13.7. DEXCOM
- 13.8. GLYSENS INC
- 13.9. INSULET CORP
- 13.10. I-SENS INC
- 13.11. JOHNSON AND JOHNSON
- 13.12. MEDTRONIC
- 13.13. MOREPEN LABORATORIES LTD
- 13.14. NEMAURA MEDICAL INC
- 13.15. ROCHE DIAGNOSTICS
- 13.16. SENSEONICS INC
- 13.17. TANDEM DIABETES CARE
- 13.18. TERUMO
- 13.19. WOCKHARDT
- 13.20. YPSOMED